APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vermox

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Vermox Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchVermox Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Vermox Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Vermox Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vermox Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Vermox Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Vermox market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vermox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vermox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vermox is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vermox market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vermox market include Amneal Pharmaceuticals, Cadila Pharmaceuticals, Eipico, Esteve Pharmaceuticals, Tenry and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vermox market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vermox and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vermox revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vermox market.

Vermox Segment by Company

Amneal Pharmaceuticals

Cadila Pharmaceuticals

Eipico

Esteve Pharmaceuticals

Tenry

Johnson & Johnson

Vermox Segment by Type

Tablet

Oral Suspension

Vermox Segment by Application

Children

Adult

Vermox Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Vermox status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vermox key companies, revenue, market share, and recent developments.

3. To split the Vermox breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vermox market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vermox significant trends, drivers, influence factors in global and regions.

6. To analyze Vermox competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vermox market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vermox and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vermox.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vermox industry.

Chapter 3: Detailed analysis of Vermox company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vermox in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vermox in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vermox Industry Trends Table 2. Vermox Industry Drivers Table 3. Vermox Industry Opportunities and Challenges Table 4. Vermox Industry Restraints Table 5. Global Vermox Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vermox Revenue Share by Company (2021-2026) Table 7. Global Vermox Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vermox Key Company Manufacturing Base & Headquarters Table 9. Global Vermox Company, Product Type & Application Table 10. Global Vermox Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vermox by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablet Table 15. Significant Companies of Oral Suspension Table 16. Global Vermox Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Vermox Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Vermox Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Vermox Sales Value Share by Type (2021-2026) Table 20. Global Vermox Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Children Table 22. Significant Companies of Adult Table 23. Global Vermox Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Vermox Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Vermox Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Vermox Sales Value Share by Application (2021-2026) Table 27. Global Vermox Sales Value Share by Application (2027-2032) Table 28. Global Vermox Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Vermox Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Vermox Sales Value Share by Region (2021-2026) Table 31. Global Vermox Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Vermox Sales Value Share by Region (2027-2032) Table 33. Global Vermox Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Vermox Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Vermox Sales Value Market Share by Country (2021-2026) Table 36. Global Vermox Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Vermox Sales Value Market Share by Country (2027-2032) Table 38. Amneal Pharmaceuticals Company Information Table 39. Amneal Pharmaceuticals Business Overview Table 40. Amneal Pharmaceuticals Vermox Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Amneal Pharmaceuticals Vermox Product Portfolio Table 42. Amneal Pharmaceuticals Recent Development Table 43. Cadila Pharmaceuticals Company Information Table 44. Cadila Pharmaceuticals Business Overview Table 45. Cadila Pharmaceuticals Vermox Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Cadila Pharmaceuticals Vermox Product Portfolio Table 47. Cadila Pharmaceuticals Recent Development Table 48. Eipico Company Information Table 49. Eipico Business Overview Table 50. Eipico Vermox Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Eipico Vermox Product Portfolio Table 52. Eipico Recent Development Table 53. Esteve Pharmaceuticals Company Information Table 54. Esteve Pharmaceuticals Business Overview Table 55. Esteve Pharmaceuticals Vermox Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Esteve Pharmaceuticals Vermox Product Portfolio Table 57. Esteve Pharmaceuticals Recent Development Table 58. Tenry Company Information Table 59. Tenry Business Overview Table 60. Tenry Vermox Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Tenry Vermox Product Portfolio Table 62. Tenry Recent Development Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Vermox Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Vermox Product Portfolio Table 67. Johnson & Johnson Recent Development Table 68. Research Programs/Design for This Report Table 69. Authors List of This Report Table 70. Secondary Sources Table 71. Primary Sources List of Figures Figure 1. Vermox Product Image Figure 2. Global Vermox Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vermox Market Size (2021-2032) & (US$ Million) Figure 4. Global Vermox Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablet Image Figure 8. Oral Suspension Image Figure 9. Global Vermox Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Vermox Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Vermox Sales Value Share by Type (2021-2032) Figure 12. Children Image Figure 13. Adult Image Figure 14. Global Vermox Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Vermox Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Vermox Sales Value Share by Application (2021-2032) Figure 17. Global Vermox Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Vermox Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Vermox Sales Value (2021-2032) & (US$ Million) Figure 20. North America Vermox Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Vermox Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Vermox Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Vermox Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Vermox Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Vermox Sales Value (2021-2032) & (US$ Million) Figure 26. South America Vermox Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Vermox Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Vermox Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Vermox Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Vermox Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Vermox Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Oral Suspension
Applications
  • Children
  • Adult
Companies covered
  • Amneal Pharmaceuticals
  • Cadila Pharmaceuticals
  • Eipico
  • Esteve Pharmaceuticals
  • Tenry
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vermox Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vermox Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vermox Market Dynamics
  1. 2.1 Vermox Industry Trends
  2. 2.2 Vermox Industry Drivers
  3. 2.3 Vermox Industry Opportunities and Challenges
  4. 2.4 Vermox Industry Restraints
3 Vermox Market by Company
  1. 3.1 Global Vermox Company Revenue Ranking in 2025
  2. 3.2 Global Vermox Revenue by Company (2021-2026)
  3. 3.3 Global Vermox Company Ranking (2024-2026)
  4. 3.4 Global Vermox Company Manufacturing Base and Headquarters
  5. 3.5 Global Vermox Company Product Type and Application
  6. 3.6 Global Vermox Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vermox Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vermox Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vermox Market by Type
  1. 4.1 Vermox Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Oral Suspension
  4. 4.2 Global Vermox Sales Value by Type
  5. 4.2.1 Global Vermox Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Vermox Sales Value by Type (2021-2032)
  7. 4.2.3 Global Vermox Sales Value Share by Type (2021-2032)
5 Vermox Market by Application
  1. 5.1 Vermox Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Vermox Sales Value by Application
  5. 5.2.1 Global Vermox Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vermox Sales Value by Application (2021-2032)
  7. 5.2.3 Global Vermox Sales Value Share by Application (2021-2032)
6 Vermox Regional Value Analysis
  1. 6.1 Global Vermox Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vermox Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vermox Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vermox Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vermox Sales Value (2021-2032)
  7. 6.3.2 North America Vermox Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vermox Sales Value (2021-2032)
  10. 6.4.2 Europe Vermox Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vermox Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vermox Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vermox Sales Value (2021-2032)
  16. 6.6.2 South America Vermox Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vermox Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vermox Sales Value Share by Country, 2025 VS 2032
7 Vermox Country-level Value Analysis
  1. 7.1 Global Vermox Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vermox Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vermox Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vermox Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vermox Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vermox Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vermox Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vermox Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vermox Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vermox Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vermox Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vermox Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vermox Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vermox Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vermox Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vermox Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vermox Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vermox Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vermox Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vermox Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vermox Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vermox Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vermox Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vermox Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vermox Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vermox Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vermox Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vermox Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vermox Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vermox Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vermox Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vermox Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vermox Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vermox Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vermox Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vermox Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vermox Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vermox Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vermox Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vermox Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vermox Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vermox Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vermox Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vermox Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vermox Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vermox Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vermox Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vermox Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vermox Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vermox Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vermox Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vermox Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vermox Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vermox Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vermox Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vermox Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vermox Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vermox Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vermox Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vermox Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vermox Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vermox Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vermox Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vermox Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vermox Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vermox Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vermox Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vermox Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vermox Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vermox Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vermox Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vermox Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vermox Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vermox Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vermox Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vermox Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vermox Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vermox Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vermox Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vermox Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vermox Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vermox Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vermox Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vermox Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vermox Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vermox Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vermox Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vermox Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amneal Pharmaceuticals
  2. 8.1.1 Amneal Pharmaceuticals Company Information
  3. 8.1.2 Amneal Pharmaceuticals Business Overview
  4. 8.1.3 Amneal Pharmaceuticals Vermox Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amneal Pharmaceuticals Vermox Product Portfolio
  6. 8.1.5 Amneal Pharmaceuticals Recent Developments
  7. 8.2 Cadila Pharmaceuticals
  8. 8.2.1 Cadila Pharmaceuticals Company Information
  9. 8.2.2 Cadila Pharmaceuticals Business Overview
  10. 8.2.3 Cadila Pharmaceuticals Vermox Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cadila Pharmaceuticals Vermox Product Portfolio
  12. 8.2.5 Cadila Pharmaceuticals Recent Developments
  13. 8.3 Eipico
  14. 8.3.1 Eipico Company Information
  15. 8.3.2 Eipico Business Overview
  16. 8.3.3 Eipico Vermox Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eipico Vermox Product Portfolio
  18. 8.3.5 Eipico Recent Developments
  19. 8.4 Esteve Pharmaceuticals
  20. 8.4.1 Esteve Pharmaceuticals Company Information
  21. 8.4.2 Esteve Pharmaceuticals Business Overview
  22. 8.4.3 Esteve Pharmaceuticals Vermox Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Esteve Pharmaceuticals Vermox Product Portfolio
  24. 8.4.5 Esteve Pharmaceuticals Recent Developments
  25. 8.5 Tenry
  26. 8.5.1 Tenry Company Information
  27. 8.5.2 Tenry Business Overview
  28. 8.5.3 Tenry Vermox Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tenry Vermox Product Portfolio
  30. 8.5.5 Tenry Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson Vermox Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson Vermox Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst